Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020)
Nektar Therapeutics (NKTR) posted quarterly Short term Debt of $254.1 million for Q1 2020, little changed quarter-over-quarter from $252.9 million in Q4 2019.
Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020) Analysis & Trends
Nektar Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $254.1 million for Q1 2020.
- In Q1 2020, Short term Debt changed N/A year-over-year to $254.1 million; the TTM figure through Mar 2020 stood at $254.1 million (changed N/A YoY), while the FY2019 annual figure was $252.9 million, changed N/A from the prior year.
- Short term Debt for Q1 2020 stood at $254.1 million, roughly flat from $252.9 million in the prior quarter.
- The five-year high for Short term Debt was $254.1 million in Q1 2020, with the low at $252.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 254.14 Mn |
| Dec 31, 2019 | 252.89 Mn |
| Sep 30, 2015 | 125.00 Mn |
| Mar 31, 2012 | 214.96 Mn |
| Dec 31, 2011 | 214.96 Mn |
| Sep 30, 2011 | 214.96 Mn |